RxDoctor Payments DataLook up a doctor →

Harry Lay

Family · Raleigh, NCNPI 1225177868

Payments from drug & device makers

$62,782in general payments, 2019–2025

Across 968 payments — averaging $64.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$14K
  • Biogen$10K
  • Novartis$7K
  • Genentech USA, Inc.$5K
  • Bristol Myers Squibb$5K
  • ANI Pharmaceuticals, Inc.$4K
  • plus $18K from 49 others

What the payments were for

  • Consulting fees$14,08922%
  • Speaking & faculty fees$24,80140%
  • Travel & lodging$4,3657%
  • Food & beverage$19,21431%
  • Education$3130%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
EMD Serono, Inc.99$14,477
Biogen35$9,914
Novartis112$6,651
Genentech USA, Inc.27$4,729
Bristol Myers Squibb101$4,695
ANI Pharmaceuticals, Inc.20$4,467
Sanofi37$3,490
E.r. Squibb & Sons, L.L.C.5$2,927
TG Therapeutics, Inc.56$1,390
AstraZeneca52$1,387
AbbVie64$1,130
UCB, Inc.27$672
Lilly USA, LLC35$529
Argenx US, Inc.23$476
Merz Pharmaceuticals, LLC17$400
Mallinckrodt Hospital Products Inc.26$393
Pfizer19$365
CSL Behring14$333
Neurocrine Biosciences, Inc.14$321
Harmony Biosciences LLC12$318
Amgen(2 entities)15$302
Acadia Pharmaceuticals Inc16$252
Vanda Pharmaceuticals Inc.9$239
Banner Life Sciences, LLC9$213
Lundbeck LLC9$213
Axsome Therapeutics, Inc.13$197
MDD US Operations, LLC10$183
Jazz Pharmaceuticals Inc.2$157
Biohaven Pharmaceutical Holding Company Ltd.8$152
Neurelis, Inc.8$151
Takeda Pharmaceuticals U.S.A., Inc.5$147
Avadel CNS Pharmaceuticals, LLC7$144
Otsuka America Pharmaceutical, Inc.7$140
Boston Scientific1$136
Johnson & Johnson7$133
Avion Pharmaceuticals7$126
Amneal Pharmaceuticals LLC6$109
Grifols USA, LLC4$94
Acorda Therapeutics, Inc4$82
Teva Pharmaceuticals USA, Inc.4$68
SK Life Science, Inc.3$66
Arbor Pharmaceuticals, Inc.3$64
Ipsen Biopharmaceuticals, Inc3$55
Genentech, Inc.1$43
Eisai Inc.2$34
Corium, LLC1$32
Mylan Specialty L.p.1$32
Catalyst Pharmaceuticals, Inc.1$31
Impel Pharmaceuticals Inc.1$25
Alnylam Pharmaceuticals Inc.1$20
Sumitomo Pharma America, Inc.1$18
Aucta Pharmaceuticals, Inc.1$17
Azurity Pharmaceuticals, Inc.1$17
Collegium Pharmaceutical, Inc.1$15
Idorsia Pharmaceuticals US Inc1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$62,782 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$54,736
Medicare patients
357
Services billed
841

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VumerityDiroximel Fumarate92$831,446
Kesimpta PenOfatumumab60$641,354
TecfideraDimethyl Fumarate37$411,980
AubagioTeriflunomide23$302,888
TysabriNatalizumab20$162,091
RebifInterferon Beta-1a/Albumin13$157,927
MayzentSiponimod12$116,991
CopaxoneGlatiramer Acetate19$108,822
FingolimodFingolimod Hcl47$95,730
Teriflunomide65$56,819
Dimethyl Fumarate14$55,857
Dalfampridine ErDalfampridine75$39,691
MyrbetriqMirabegron37$35,261
QuliptaAtogepant27$32,761
Nurtec OdtRimegepant Sulfate18$29,808

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity, Tecfidera, Tysabri$9,914$1,405,517149 claims
SanofiAubagio$3,490$302,88823 claims
EMD Serono, Inc.Rebif$14,477$157,92713 claims
NovartisMayzent$6,651$116,99112 claims
Teva Pharmaceuticals USA, Inc.Copaxone$68$108,82219 claims
AbbVieQulipta, Ubrelvy$1,130$56,35748 claims
PfizerNurtec Odt, Lyrica$365$41,87331 claims
UCB, Inc.Vimpat$672$15,88314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →